Evaluation of the Safety of Taking Brexpiprazole During the Lactation Period.

Akari Fukuda; Gen Oyanagi; Saya Kikuchi; Chihiro Iwasaki; Miyu Okubo; Aoi Noda; Kei Morishita; Nao Okabe; Riko Iwabuchi; Ai Abe; Erika Kimura; Natsuko Kobayashi; Hasumi Tomita; Shinichi Sato; Noriyuki Iwama; Takushi Hanita; Masatoshi Saito; Hiroaki Tomita; Taku Obara; Nariyasu Mano

doi:10.1177/15568253251408037

Key Points

The aim is to evaluate the safety of brexpiprazole during the lactation period and its effects on infants.
Evaluated brexpiprazole monotherapy at doses of 1-2 mg/day
Monitored newborns and infants for withdrawal symptoms and adverse events
Assessed outcomes within the first month postpartum
No withdrawal symptoms observed in newborns or infants
No serious adverse events reported during the study
Initial evidence supports safety of brexpiprazole use during lactation

Implication

Evaluates the impact of brexpiprazole on newborns in lactating mothers, suggesting safety in breastfeeding decisions.

Abstract

This study suggests that BPZ monotherapy (1-2 mg/day) during lactation does not lead to withdrawal symptoms or serious adverse events in newborns or infants within the first month postpartum. This initial evidence may help inform breastfeeding decisions among mothers receiving BPZ monotherapy.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Fukuda et al. (2026) studied this question.

synapsesocial.com/papers/698827b40fc35cd7a8846a26 https://doi.org/10.1177/15568253251408037

View at Publisher

Ask AI

Bookmark

Share

Evaluation of the Safety of Taking Brexpiprazole During the Lactation Period.

Key Points

Implication

Abstract

Discussion

Cite This Study

Evaluation of the Safety of Taking Brexpiprazole During the Lactation Period.

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

Keep reading

More related papers